WELCH DANIEL G — SEC Form 4 filings
SEC reporting owner CIK 1206199. 11 Form 4 filings on record with FilingPulse; latest filed 2026-06-18.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-02-23 to 2026-06-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | Director | 3 | — | — | 6 |
| Nuvation Bio Inc. (NUVB) | Director | 1 | — | — | 4 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Director | 4 | — | — | 4 |
| Structure Therapeutics Inc. (GPCR) | Director | 3 | — | — | 3 |
Form 4 filings — WELCH DANIEL G
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-18 | 4 | Structure Therapeutics Inc. (GPCR) | Grant/award (A): 39,453 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 7,751 @ $0 · Grant/award (A): 14,058 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | Structure Therapeutics Inc. (GPCR) | Grant/award (A): 51,804 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 5,740 @ $0 · Grant/award (A): 10,787 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Grant/award (A): 20,183 (derivative) @ $0 | EDGAR |
| 2024-06-27 | 4 | Structure Therapeutics Inc. (GPCR) | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Ultragenyx Pharmaceutical Inc. (RARE) | Grant/award (A): 5,345 @ $0 · Grant/award (A): 9,900 (derivative) @ $0 | EDGAR |
| 2024-05-29 | 4 | Nuvation Bio Inc. (NUVB) | Option exercise (M): 293,203 @ $1.74 · Option exercise (M): 366,744 @ $1.64 · Option exercise (M): 293,203 (derivative) @ $0 · Option exercise (M): 366,744 (derivative) @ $0 | EDGAR |
| 2024-05-17 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-02-23 | 4 | PROTHENA CORP PUBLIC LTD CO (PRTA) | Grant/award (A): 132,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1206199 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →